The incidence rates of both NEPC and DNPC have notably increased following the introduction of second-line antiandrogens into the drug regimen of patients (78, 82), and NEPC and DNPC exhibit worse survival outcomes compared to AR-positive prostate cancer (79, 83). The gene discussed is AR; the disease is prostate cancer.